Το RINVOQ® είναι ένας χορηγούμενος από του στόματος εκλεκτικός και αναστρέψιμος JAK αναστολέας που ενδείκνυται για τη θεραπεία της μέτριας έως σοβαρής ατοπικής δερματίτιδας σε ενήλικες και εφήβους ηλικίας 12 ετών και άνω που είναι υποψήφιοι για συστηματική θεραπεία.1
*Ενδεικτική βαρύτητα νόσου βάσει του EASI Score.
† Η περιοχική βαθμονόμηση (0–6) εξαρτάται από την % συμμετοχή των συμπτωμάτων του δέρματος. Οι περιοχές του σώματος είναι το κεφάλι/λαιμός, ο κορμός, τα άνω και κάτω άκρα..
‡ MCID: Minimum clinically important difference, ορίζεται ως βελτίωση ≥4 βαθμών από την αρχική τιμή στη κλίμακα κνησμού.
ΒΙΒΛΙΟΓΡΑΦΙΑ
- RINVOQ Περίληψη Χαρακτηριστικών Προϊόντος 07-2023.
- Guttman-Yassky E, Teixeira H, Simpson E, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021; 397(10290): 2151-2168.
- Simpson EL, Papp KA, Blauvelt A,et al. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029.
- Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. Published online August 4, 2021. doi:10.1001/jamadermatol.2021.3023..
- European Medicines Agency. RINVOQ EPAR: Public Assessment Report. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq. Accessed December 2023
- Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2169–81.
- Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020;383(16):1511–1521.
- Kameda H, Takeuchi T, Yamaoka K, et al. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology (Oxford). 2020;59(11):3303–3313.
- Zeng X, Zhao D, Radominski SC, et al. Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy. Int J Rheum Dis. 2021 Dec;24(12):1530-1539. doi: 10.1111/1756-185X.14235.
- ClinicalTrials.gov. A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Rising Up). Available at: https://clinicaltrials.gov/ct2/show/NCT03661138 Accessed December 2023
- Leshem YA, et al. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015; 172(5): 1353–1357.
- Homeforeczema.org. EASI User Guide Dec 2016. Available at :http://www.homeforeczema.org/documents/easi-user-guide-dec-2016-v2.pdf. Accessed December 2023
- Phan NQ, Blome C, Fritz F, et al. Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus. Acta Derm Venereol 2012; 92(5): 502–507.
- Reich A, Heisig M, Phan NQ, et al. Visual Analogue Scale: Evaluation of the Instrument for the Assessment of Pruritus. Acta Derm Venereol 2012; 92(5): 497–501.
- Silverberg JI, Simpson EL, Calimlim BM, Litcher-Kelly L, et al. Dermatol Ther (Heidelb). 2022 Dec;12(12):2817-2827. doi: 10.1007/s13555-022-00836-5.